A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...
Pharmaceutical Technology on MSN
Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify
Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to continue in 2026.
Speed limits have been around longer than you might expect. The story of the very first speeding ticket shows just how different early motoring laws were.
As giant companies, especially in technology, propel the S&P 500 to new heights, a select group of mid-sized companies are ...
A Division Bench of Delhi High Court on Friday declined to stay a Single Judge’s order that had allowed Dr Reddy’s ...
CPTech secured patents in Saudi Arabia and the U.S. for its core pyrolysis oil upgrading process, part of its campaign to ...
Novo Nordisk Moves to higher Bench to Block Dr. Reddy’s Semaglutide Exports ...
GM has filed to trademark the term Infinite Route for a second time. The term may be used in conjunction with the automaker's ...
The House approved a measure Thursday to reinstate collective bargaining rights to federal workers, a step toward restoring ...
Ron DiCerbo of McAndrews, Held & Malloy, Ltd. discusses how brand owners can use Schedule A litigation to efficiently combat ...
Zacks Investment Research on MSN
AbbVie slipped below 50-day SMA last week: How to play the stock
AbbVie’s ABBV stock slipped below its 50-day simple moving average (SMA) late last week. The stock has also declined by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results